BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 26710352)

  • 1. The evolution of anticoagulant therapy.
    Franchini M; Liumbruno GM; Bonfanti C; Lippi G
    Blood Transfus; 2016 Mar; 14(2):175-84. PubMed ID: 26710352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
    Beyer-Westendorf J; Ageno W
    Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of direct oral anticoagulants for the treatment of cancer-associated thrombosis: an update.
    Franco-Moreno A; Cabezón-Gutiérrez L; Palka-Kotlowsa M; Villamayor-Delgado M; García-Navarro M
    J Thromb Thrombolysis; 2019 Apr; 47(3):409-419. PubMed ID: 30467760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of the Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism.
    Riva N; Ageno W
    Hematol Oncol Clin North Am; 2016 Oct; 30(5):1035-51. PubMed ID: 27637306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?
    Laux V; Perzborn E; Heitmeier S; von Degenfeld G; Dittrich-Wengenroth E; Buchmüller A; Gerdes C; Misselwitz F
    Thromb Haemost; 2009 Nov; 102(5):892-9. PubMed ID: 19888525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism.
    Chan NC; Bhagirath V; Eikelboom JW
    Vasc Health Risk Manag; 2015; 11():343-51. PubMed ID: 26170684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factor Xa and thrombin as targets for new oral anticoagulants.
    Weitz JI
    Thromb Res; 2011 Jan; 127 Suppl 2():S5-S12. PubMed ID: 21193114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer-associated thrombosis: investigating the role of new oral anticoagulants.
    Franchini M; Bonfanti C; Lippi G
    Thromb Res; 2015 May; 135(5):777-81. PubMed ID: 25743884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insights into direct anticoagulants.
    Saad E; Dally N
    Blood Coagul Fibrinolysis; 2015 Jul; 26(5):492-8. PubMed ID: 25828968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-vitamin K antagonist oral anticoagulants (NOACs): clinical evidence and therapeutic considerations.
    Saraf K; Morris PD; Garg P; Sheridan P; Storey R
    Postgrad Med J; 2014 Sep; 90(1067):520-8. PubMed ID: 25085900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Established venous thromboembolism therapies: heparin, low molecular weight heparins, and vitamin K antagonists, with a discussion of heparin-induced thrombocytopenia.
    Pendleton RC; Rodgers GM; Hull RD
    Clin Chest Med; 2010 Dec; 31(4):691-706. PubMed ID: 21047576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of anticoagulants: an overview of current developments.
    Greinacher A; Thiele T; Selleng K
    Thromb Haemost; 2015 May; 113(5):931-42. PubMed ID: 25832311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practical management of rivaroxaban for the treatment of venous thromboembolism.
    Imberti D; Benedetti R
    Clin Appl Thromb Hemost; 2015 May; 21(4):309-18. PubMed ID: 24057396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathophysiology and pharmacologic treatment of venous thromboembolism.
    Bain J; Oyler DR; Smyth SS; Macaulay TE
    Curr Drug Targets; 2014 Feb; 15(2):199-209. PubMed ID: 24102472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [News on antithrombotic therapy and pregnancy].
    Chauleur C; Gris JC; Seffert P; Mismetti P
    Therapie; 2011; 66(5):437-43. PubMed ID: 22031688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New anticoagulants: from bench to bedside.
    Haas S; Schellong S
    Hamostaseologie; 2007 Feb; 27(1):41-7. PubMed ID: 17279275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
    Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin?
    Arepally GM; Ortel TL
    Annu Rev Med; 2015; 66():241-53. PubMed ID: 25587651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brave new world: the current and future use of novel anticoagulants.
    Spyropoulos AC
    Thromb Res; 2008; 123 Suppl 1():S29-35. PubMed ID: 18835010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran.
    Fanola CL
    Vasc Health Risk Manag; 2015; 11():271-82. PubMed ID: 26064057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.